Spineway SA (37S) Stock Price & Analysis
37S Stock Chart & Stats
- Day’s Range
- EUR 0.08 - EUR 0.09
- 52-Week Range
- EUR 0.08 - EUR 0.21
- Previous Close
- EUR 0.09
- Volume
- 0
- Average Volume (3M)
- 502
- Market Cap
- EUR 3.09M
- Enterprise Value
- EUR 3.44M
- Total Cash (Recent Filing)
- EUR 3.50M
- Total Debt (Recent Filing)
- EUR 1.53M
- Price to Earnings (P/E)
- ―
- Beta
- 0.55
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Steady Revenue Growth
Steady multi-year revenue growth indicates expanding commercial activity for Spineway’s spinal implants and surgical systems. If maintained, this trend can broaden the company’s operating base, support greater scale, and provide a foundation for improving profitability as sales increase.
Gross Margin Recovery
The recovery in gross margin shows that Spineway’s product economics have improved materially from earlier periods. Sustaining better margins would increase the contribution available to cover operating costs, support reinvestment, and improve the prospect of reaching durable profitability.
Conservative Leverage
Very low leverage gives Spineway greater financial resilience while it works toward profitability. A conservative capital structure reduces debt-related pressure, preserves borrowing capacity if needed, and leaves more flexibility to fund commercial development without relying heavily on creditors.
Bears Say
Persistent Net Losses
Spineway’s continued net losses show that revenue growth and gross-margin recovery have not yet translated into sustainable earnings. Persistent losses can constrain internally funded investment, weaken return potential, and make future performance dependent on further operational improvement.
Weak Free Cash Flow
The absence of positive free cash flow indicates that Spineway is not yet generating surplus cash after investment needs. This limits financial flexibility, reduces the resources available for growth or debt reduction, and leaves less room to absorb setbacks while losses continue.
Negative Return On Equity
Negative return on equity confirms that Spineway’s sizable equity base is not yet producing positive earnings. Until operating improvements convert into profits, capital efficiency will remain weak and shareholders may see limited evidence that the balance sheet is creating economic value.
Spineway SA News
37S FAQ
What was Spineway SA’s price range in the past 12 months?
What is Spineway SA’s market cap?
When is Spineway SA’s upcoming earnings report date?
How were Spineway SA’s earnings last quarter?
Is Spineway SA overvalued?
Does Spineway SA pay dividends?
What is Spineway SA’s EPS estimate?
How many shares outstanding does Spineway SA have?
What happened to Spineway SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Spineway SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Spineway SA
Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion products, such as lumbar cage twin peaks tlif curved and oblique; motion preservation products; and biomaterials. It also exports its products. The company was incorporated in 2005 and is headquartered in Ecully, France.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Stéphane Le Roux
- Employees
- 43
- Website
- www.spineway.com
- Address
- 7, allEe Moulin Berger, Ecully, AR, 69130, FR
Spineway SA (37S) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |